GPCR — Structure Therapeutics Inc. stock price, charts and financials

QT83Structure Therapeutics Inc.

Structure Therapeutics Inc. (NASDAQ: GPCR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
52.75
-0.39-0.73%
OverviewShort InterestFilings
GPCRQT83Structure Therapeutics Inc.·NASDAQ
52.75-0.73%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
GRAL+6.50%$74.00IRON+0.35%$77.71ARQT+1.62%$25.70QURE-0.56%$46.16MBX-3.09%$65.72NAMS-0.46%$27.83KOD-4.66%$43.26IOVA+2.43%$6.49
Snapshot
Index-P/E-EPS (ttm)-Insider Own39.44%Shs Outstand57.57MPerf Week10.62%
Market Cap3.06BForward P/E-EPS next Y-1.98Insider Trans-0.24%Shs Float54.73MPerf Month-3.63%
Enterprise Value2.79BPEG1.24EPS next Q-Inst Own-Short Float11.34%Perf Quarter35.73%
Income-170.39MP/S0.00EPS this Y-Inst Trans-Short Ratio7.58Perf Half Y-27.41%
Sales0.00P/B2.85EPS next Y-38.02%ROA-15.09%Short Interest6.21MPerf YTD-23.59%
Book/sh-P/C-EPS next 5Y-ROE-16.91%52W High94.20 -44.00%Perf Year225.81%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-18.95%52W Low15.73 235.27%Perf 3Y66.79%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.14% 5.32%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM32.91%Oper. Margin0.00%ATR (14)2.64Perf 10Y-
Dividend Ex-Date-Quick Ratio20.75Sales Y/Y TTM-Profit Margin0.00%RSI (14)61.30Recom2.00
Dividend Gr. 3/5Y-Current Ratio20.75EPS Q/Q-29.63%SMA207.49%Beta0.83Target Price108.67
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA5012.43%Rel Volume0.46Prev Close53.14
Employees220LT Debt/Eq0.00EarningsNov 05SMA2001.20%Avg Volume712.13KPrice52.75
IPO DateFeb 03, 2023Option/ShortYes / YesEPS/Sales Surpr.0.34% -Net Debt/EBITDA1.25Volume329,348Change-0.73%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedCanaccord Genuity$101 → $111
Jun-11-26ReiteratedHC Wainwright & Co.Buy$90 → $70
Apr-27-26InitiatedCanaccordBuy$101
Mar-17-26ReiteratedBMO CapitalOutperform$100 → $145
Jan-20-26ReiteratedGuggenheimBuy$140
Jan-19-26ReiteratedGoldman Sachs$102
Dec-19-25ReiteratedHC Wainwright & Co.Buy$60 → $90
Dec-12-25ReiteratedMorgan StanleyOverweight$118 → $125
Dec-11-25ReiteratedJefferiesBuy$125
Dec-08-25ReiteratedStifel Nicolaus$50 → $90
Latest News
Company

Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue
000———
Cost of Goods Sold Incl. D&A400———
Gross Profit-400———
Selling, General and Administrative Excl. Other624933———
Research and Development22510970———
Other Operating Expense-300———
Operating Income-288-158-103———
Interest Expense0013———
Unusual Expense
——————
Non-Operating Income (Expense)1473627———
Net Income Before Taxes-141-122-89———
Income Taxes100———
Consolidated Net Income-141-123-90———
Net Income From Continuing Operations-141-123-90———
Net Income-141-123-90———
EPS (Recurring)-2.40-2.34-2.43———
EPS (Basic, Before Extraordinaries)-2.40-2.34-2.43———
EPS (Diluted)-2.40-2.34-2.43———
EBITDA-137-121-76———
Other After Tax Adjustments
——————
Stock Option Compensation Expense
——————
Price To Earnings Ratio
——————
Price To Sales Ratio
——————
Gross Margin
——————
Operating Margin
——————
Net Margin
——————
Shares Outstanding595337———
Market Capitalization4,1031,4371,508———
Operating Lease Expense
——————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$105.43$80.21$55.00$29.78$4.56● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Lin XichenCHIEF SCIENTIFIC OFFICERAug 04 '26Option Exercise0.3411,8174,018240,777Aug 05
Lin XichenCHIEF SCIENTIFIC OFFICERAug 04 '26Sale0.003,93900Aug 05
FMR LLC10 percent owner, other: See Remark 1Jul 22 '26Sale0.0017,45201,369Jul 24
Lin XichenCHIEF SCIENTIFIC OFFICERJul 14 '26Option Exercise0.3423,6348,036252,594Jul 15
Lin XichenCHIEF SCIENTIFIC OFFICERJul 14 '26Sale0.007,87800Jul 15
Lin XichenCHIEF SCIENTIFIC OFFICERJun 25 '26Option Exercise0.3423,6348,036252,594Jun 29
Lin XichenCHIEF SCIENTIFIC OFFICERJun 25 '26Sale0.007,87800Jun 29
FMR LLC10 percent owner, other: See Remark 1Apr 14 '26Sale0.0017,45202,736Apr 16
FMR LLC10 percent owner, other: See Remark 1Jan 15 '26Sale0.0017,45204,103Jan 20
FMR LLC10 percent owner, other: See Remark 1Dec 08 '25Sale0.0052,35600Dec 10
FMR LLC10 percent owner, other: See Remark 1Jul 30 '25Sale0.0026,31001,515,558Aug 01
FMR LLC10 percent owner, other: See Remark 1Feb 06 '25Sale0.004100Feb 10
Stevens Raymond CCHIEF EXECUTIVE OFFICERJun 12 '24Option Exercise0.42150,00063,000793,346Jun 14
Stevens Raymond CCHIEF EXECUTIVE OFFICERJun 10 '24Sale0.00185,00000Jun 12
Lin XichenCHIEF SCIENTIFIC OFFICERJun 03 '24Sale0.0035,40000Jun 05
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.